-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Alzheimer's disease (AD) has a preclinical window period, up to 20 years, and its pathological features are tau and β-amyloid.
This study aims to investigate the relationship between SCD, anxiety and depression symptoms, and amyloid status in people under 70 years of age.
The article hypothesizes that after considering anxiety and depression factors, amyloid positivity is associated with greater SCD.
Anxious MyCog Total Score
The AD8 score was significantly correlated with the MyCog score, indicating that the participants and the collector had the same views: the MyCog score increased by 0.
Amyloid positivity was associated with SCD symptoms and was previously associated with poor objective cognitive performance in this cohort, but after considering amyloid status, there was no statistically significant relationship between MyCog score and objective cognitive performance.
The results of the study show that if the effects of anxiety symptoms are carefully considered, the presence of subjective cognitive symptoms may help identify patients with Alzheimer’s.
The results of the study show that if the effects of anxiety symptoms are carefully considered, the presence of subjective cognitive symptoms may help identify patients with Alzheimer’s.
Leave a message here